Online Automated Self-Hypnosis Program

Trial ID or NCT#

NCT03931772

Status

not recruiting iconNOT RECRUITING

Purpose

After developing professional quality materials (audio) for an affordable automated self-hypnosis intervention program for facilitating smoking cessation, stress and pain reduction, researchers aim to gain qualitative reviews of this program, and test its initial feasibility and effects on smoking cessation and reduction in pain and stress. In addition, this study seeks to determine whether higher hypnotizability, as measured by the Hypnotic Induction Profile (assessed at baseline), is a moderator of improved outcome in these conditions.

Official Title

Pilot Study Evaluating the Feasibility and Effects of an Innovative Automated Hypnosis Intervention for Smoking Cessation and Pain and Stress Reduction

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. - 18 years or older - Able to read and understand English - For the smokers, desire to quit smoking (specifically, report a motivation of ≥ 5 out of 10 to quit smoking on a 10-point Likert-type scale), and report being a daily smoker for at least one year, smoking an average ≥ 5 cigarettes per day - For the pain group, report suffering from chronic pain syndromes, such as fibromyalgia or chronic low back pain - For the stress group, report experiencing moderate to extreme stress or anxiety in the past month - Having access to wireless internet connection or mobile data
Exclusion Criteria:
  1. - Meeting criteria for drug abuse, including use of dissociative anesthetics, hallucinogens, opioids, cocaine, or amphetamine within the last 3 months - Severe psychiatric or structural brain disease (i.e. psychosis, stroke with functional impairment, dementia) or current/recent risk to self - Hearing impairment that would impede ability to listen the auditory intervention - Major illnesses impacting the study results - For smokers, currently taking Wellbutrin, Chantix, or other pharmacological smoking cessation aids that could confound results of the study
View All Criteria
Show Less

Investigator(s)

David Spiegel
David Spiegel
Psychiatrist
Jack, Lulu and Sam Willson Professor of Medicine

Contact us to find out if this trial is right for you.

Contact

David Spiegel
650-723-6421

View on ClinicalTrials.gov